Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Chu

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?Tomas Merino Lara, Joelle Helou, Ian Poon, et al.
Circulation Research|March 11, 2020
Deep Phenotyping by Mass Cytometry and Single-Cell RNA-Sequencing Reveals LYN-Regulated Signaling Profiles Underlying Monocyte Subset Heterogeneity and LifespanMorgan E Roberts, Maunish Barvalia, Jessica A F D Silva, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation StudyYasir Alayed, Andrew Loblaw, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|November 17, 2018
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal IrradiationYasir Alayed, Patrick Cheung, Danny Vesprini, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trialsRachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
Annals of Palliative Medicine|April 29, 2016
Radiological changes on CT after stereotactic body radiation therapy to non-spine bone metastases: a descriptive seriesNicholas Chiu, Linda Probyn, Srinivas Raman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2020
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boostYasir Alayed, Andrew Loblaw, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 24, 2019
Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matterRobert Thompson, Patrick Cheung, William Chu, et al.
Cancer|December 22, 2017
Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)Shankar Siva, Alexander V Louie, Andrew Warner, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?Tomas Merino Lara, Joelle Helou, Ian Poon, et al.
Circulation Research|March 11, 2020
Deep Phenotyping by Mass Cytometry and Single-Cell RNA-Sequencing Reveals LYN-Regulated Signaling Profiles Underlying Monocyte Subset Heterogeneity and LifespanMorgan E Roberts, Maunish Barvalia, Jessica A F D Silva, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation StudyYasir Alayed, Andrew Loblaw, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|November 17, 2018
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal IrradiationYasir Alayed, Patrick Cheung, Danny Vesprini, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trialsRachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
Annals of Palliative Medicine|April 29, 2016
Radiological changes on CT after stereotactic body radiation therapy to non-spine bone metastases: a descriptive seriesNicholas Chiu, Linda Probyn, Srinivas Raman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2020
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boostYasir Alayed, Andrew Loblaw, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 24, 2019
Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matterRobert Thompson, Patrick Cheung, William Chu, et al.
Cancer|December 22, 2017
Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)Shankar Siva, Alexander V Louie, Andrew Warner, et al.
Pageof 13